Related Experiment Video
Updated: May 8, 2026
07:55
Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
β-Amyloid precursor protein: function in stem cell development and Alzheimer's disease brain
David H Small1, Yanling Hu, Marta Bolós
1Menzies Research Institute Tasmania and School of Medicine, University of Tasmania, Hobart, Tas., Australia.
Neuro-Degenerative Diseases
|August 15, 2013
Summary
Alzheimer's disease (AD) research reveals that the beta-amyloid precursor protein (APP) promotes neural stem cell growth and neuronal differentiation. This effect is mediated by cystatin C, a protein with therapeutic potential for AD.
Area of Science:
- Neuroscience
- Stem cell biology
- Molecular biology
Background:
- Neurodegenerative diseases, including Alzheimer's disease (AD), are a significant health concern.
- Stem cell therapy offers potential for treating these conditions, but understanding neural stem cell (NSC) regulation is crucial.
- The beta-amyloid precursor protein (APP) is implicated in AD pathogenesis and may influence NSC behavior.
Purpose of the Study:
- To investigate the role of APP in NSC proliferation and differentiation.
- To identify the mechanisms by which APP affects NSC behavior.
- To explore the therapeutic potential of identified factors in AD.
Main Methods:
- In vitro studies using neural stem or progenitor cells.
- Analysis of APP's effect on cell proliferation and neuronal differentiation.
- Identification of mediating autocrine factors.
Main Results:
- APP was found to stimulate both proliferation and neuronal differentiation of neural stem/progenitor cells in vitro.
- The proliferative effect of APP is mediated by an autocrine factor identified as cystatin C.
- Cystatin C has also been shown to inhibit amyloid pathology in mouse models.
Conclusions:
- APP plays a role in regulating neural stem cell behavior, promoting proliferation and neuronal differentiation.
- Cystatin C is an autocrine factor mediating APP-induced proliferation.
- Cystatin C represents a potential therapeutic target for Alzheimer's disease due to its dual role in NSC regulation and amyloid pathology inhibition.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...